Agenus to Provide Corporate Update and First Quarter 2021 Financial Report
April 22, 2021 16:05 ET
|
Agenus Inc.
LEXINGTON, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
April 19, 2021 08:30 ET
|
Agenus Inc.
Submission has been made for review under the accelerated approval pathway LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an...
Agenus Doses First Cancer Patient with iNKT Cell Therapy
April 14, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
New Clinical Responses for AGEN1181 Presented at AACR
April 10, 2021 08:35 ET
|
Agenus Inc.
7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen in patients typically unresponsive to I-O agents ...
Agenus to Participate in Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations
April 06, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
March 15, 2021 07:45 ET
|
Agenus Inc.
Completion of balstilimab BLA filing on target for 1H 2021New clinical data for AGEN1181 to be presented at AACRTIGIT bispecific AGEN1777 IND to be filed in 2Q 2021iNKT cell therapy cancer trials to...
Agenus to Present New Clinical Data on AGEN1181 at AACR 2021
March 10, 2021 16:33 ET
|
Agenus Inc.
Clinical benefit in previously unresponsive tumors, including CRC, ovarian, and endometrialConfirmed responses in cold tumors as characterized by MSSNo neuroendocrine toxicities or...
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
March 02, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Andy Hurley Named Agenus Chief Commercial Officer
February 09, 2021 17:06 ET
|
Agenus Inc.
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
Agenus Announces Agenus Insights - Virtual R&D Miniseries
February 09, 2021 11:00 ET
|
Agenus Inc.
Season 1 Episode 1 (S1E1) on “Optimally Targeting TIGIT” LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of...